Trials / Completed
CompletedNCT00034593
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALIMTA | |
| DRUG | gemcitabine |
Timeline
- First posted
- 2002-05-01
- Last updated
- 2006-07-19
Locations
9 sites across 3 countries: Finland, France, Germany
Source: ClinicalTrials.gov record NCT00034593. Inclusion in this directory is not an endorsement.